New weight loss drug candidate enters first human tests
NCT ID NCT07487376
First seen Apr 08, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called IBIO-600 in 32 overweight or obese adults. The main goal is to find a safe and tolerable dose by checking for side effects and how the drug moves through the body. Participants receive a single dose and are monitored closely. This is a first step to see if the drug might help with weight management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Veritus Research
Bayswater, Victoria, 3153, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.